2026-04-29T22:51:02Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/226872024-11-28T17:37:50Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16961col_20.500.12105_16963col_20.500.12105_16967col_20.500.12105_16982

00925njm 22002777a 4500 dc Perez de Llano, Luis Alejandro author García-Cosío, Borja author Domingo, Christian author Urrutia, Isabel author Bobolea, Irina author Valero, Antonio author Entrenas, Luis M author Quirce, Santiago author Barranco, Pilar author Marina Malanda, Nuria author Prieto Andres, Luis author Alvarez-Gutierrez, Francisco J author 2019-09 BACKGROUND: Patients with severe allergic and eosinophilic asthma could qualify for different biologic therapies. OBJECTIVE: To evaluate the efficacy and safety of weight-based intravenous reslizumab dosing in patients who have previously failed therapy with omalizumab. METHODS: We carried out a 24-week prospective, multicenter, open-label, single-group, self-controlled study in patients with severe eosinophilic asthma who had previously failed to respond to omalizumab. The main objective was to determine whether treatment with reslizumab significantly improved asthma symptoms assessed by the Asthma Control Test (ACT) at week 24. Secondary objectives were to evaluate symptoms at weeks 4 and 12, change in FEV1 at week 24, and the incidence of severe exacerbations over the study period. RESULTS: Twenty-nine patients (62.1% women, median age, 50.8 years) were included in the study. The median ACT score significantly increased from 13.0 (interquartile range, 8.0-18.0) at baseline to 21.0 (interquartile range, 14.0-24.0) at 24 weeks (P=.002). Only 2 of 29 patients developed at least 1 severe exacerbation during follow-up and none of them required hospitalization. Overall, 15 of 25 patients (60%) were considered as being controlled (ACT score of >= 20 and no exacerbations) at week 24. The percentage of patients who were receiving daily systemic corticosteroids significantly decreased from 72.4% to 52.0% (P=.019). Adverse events were mostly moderate and within the range of previously reported side effects with reslizumab. CONCLUSION: Reslizumab is an effective and safe option for patients with severe eosinophilic asthma and a history of omalizumab failure. Perez De Llano LA, Cosio BG, Domingo C, Urrutia I, Bobolea I, Valero A, et al. Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study. J Allergy Clin Immunol-Pract. 2019 Sep;7(7):2277-83.e2. Epub 2019 Jan 21. 10.1016/j.jaip.2019.01.017 2213-2201 2213-2198 Journal of Allergy and Clinical Immunology-In Practice http://hdl.handle.net/20.500.13003/17261 30677539 L2001594147 2-s2.0-85061706661 https://hdl.handle.net/20.500.12105/22687 484456300028 Asthma Asthma management Severe asthma Omalizumab Reslizumab Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study